{rfName}
Ri

Indexed in

Altmetrics

Analysis of institutional authors

Llamas-Velasco, MarAuthor

Share

January 3, 2026
Publications
>
Article
No

Risk of adverse events of psoriasis treatment with biologic agents and new small molecules-BIOBADADERM Registry

Publicated to: Journal Of The European Academy Of Dermatology And Venereology. 39 (9): 1643-1655 - 2025-05-19 39(9), DOI: 10.1111/jdv.20738

Authors:

Olivares-Guerrero, Maria; Dauden, Esteban; Riera-Monroig, Josep; Gonzalez-Quesada, Alicia; Sahuquillo-Torralba, Antonio; Rivera-Diaz, Raquel; Carrascosa, Jose Manuel; Belinchon, Isabel; Gomez-Garcia, Francisco Jose; Herrera-Acosta, Enrique; Ruiz-Genao, Diana P; Ruiz-Genao, Diana P; Baniandres-Rodriguez, Ofelia; Ferran, Marta; de la Cueva, Pablo; Rodriguez, Lourdes; Mateu, Almudena; Ruiz-Carrascosa, Jose Carlos; Ara-Martin, Mariano; Abalde-Pintos, Maria Teresa; Roncero-Riesco, Monica; Pujol-Marco, Conrad; Garcia-Donoso, Carmen; Llamas-Velasco, Mar; Del Alcazar, Elena; Suarez-Perez, Jorge; Rodriguez-Sanchez, Belen; Diez-Madueno, Kevin; Ruiz-Villaverde, Ricardo; Lezcano-Biosca, Victoria; Gonzalez-Sixto, Beatriz; Descalzo, Miguel angel; Garcia-Doval, Ignacio
[+]

Affiliations

Complejo Hosp Univ Pontevedra, Dept Dermatol, Pontevedra, Spain - Author
Complexo Hosp Univ Vigo, Dermatol Dept, Pontevedra, Spain - Author
Hosp Clin Univ Lozano Blesa, Dept Dermatol, Zaragoza, Spain - Author
Hosp Gen Univ Gregorio Maranon, CEIMI, Dept Dermatol, Madrid, Spain - Author
Hosp Mar, Parc Salut Mar, Dept Dermatol, Barcelona, Spain - Author
Hosp San Cecilio, Dept Dermatol, Granada, Spain - Author
Hosp Univ & Politecn La Fe, Dept Dermatol, Valencia, Spain - Author
Hosp Univ Doctor Peset, Dept Dermatol, Valencia, Spain - Author
Hosp Univ Fdn Alcorcon, Dept Dermatol, Madrid, Spain - Author
Hosp Univ Gran Canaria Dr Negrin, Dept Dermatol, Hosp Univ Gran Canaria Dr, Las Palmas Gran Canaria, Spain - Author
Hosp Univ Infanta Leonor, Dept Dermatol, Madrid, Spain - Author
Hosp Univ Reina Sofia, Dept Dermatol, Cordoba, Spain - Author
Hosp Univ Salamanca, Dept Dermatol, Salamanca, Spain - Author
Hosp Univ Virgen Victoria, Dept Dermatol, Malaga, Spain - Author
Hosp Virgen Rocio, Dept Dermatol, Seville, Spain - Author
Inst Invest Sanitaria Princesa IIS LP, Hosp Univ Princesa, Dept Dermatol, Madrid, Spain - Author
ISABIAL UMH, Hosp Gen Univ Dr Balmis, Dept Dermatol, Alicante, Spain - Author
Spanish Acad Dermatol & Venereol, Ferraz 100,1 Izda, Madrid 28008, Spain - Author
Spanish Acad Dermatol & Venereol, Res Unit, Madrid, Spain - Author
UB, Hosp Clin Barcelona, Dept Dermatol, Barcelona, Spain - Author
Univ Autonoma Barcelona, Hosp Univ Germans Trias i Pujol, Dept Dermatol, Dept Med, Barcelona, Spain - Author
Univ Complutense, Hosp Univ 12 Octubre, Dept Dermatol, Madrid, Spain - Author
See more

Abstract

BackgroundRegistry studies are needed to provide comprehensive and updated assessments of the long-term safety profiles of systemic drugs in psoriasis.ObjectiveTo analyse the safety of biologic drugs and new oral molecules used for the treatment of moderate-to-severe psoriasis in patients included in the Spanish Registry of Adverse Events of Biological Therapy (BIOBADADERM), compared to that of adalimumab.MethodsProspective, multicentre cohort of patients with psoriasis. The safety profiles of biologic agents (etanercept, infliximab, adalimumab, certolizumab, ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab and tildrakizumab), apremilast and dimethyl fumarate were studied. The incidence rate ratio (IRR) and adjusted IRR of specific adverse events were assessed for each drug, using adalimumab as a reference. Propensity scores were used to adjust for selection bias.ResultsOur study included 4212 patients (7590 treatment cycles; 17,284 patient-years of follow-up). Adalimumab had an incidence rate for all adverse events of 614 per 1000 patient-years (95% confidence interval [CI] (591; 637)). The risk of all adverse events was significantly lower for guselkumab (adjusted IRR [aIRR] 0.56, 95% CI (0.47; 0.67)), risankizumab (aIRR 0.59, 95% CI (0.48; 0.71)), tildrakizumab [aIRR 0.6, 95% CI (0.46; 0.8)], ixekizumab (aIRR 0.65, 95% CI (0.56; 0.76)) and ustekinumab (aIRR 0.73 95% CI (0.65; 0.82)) compared to adalimumab (p
[+]

Keywords

EfficacyLongitudinal assessmentMetaanalysisSafetySurvivalSystemic drugsTherapy

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Journal Of The European Academy Of Dermatology And Venereology due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2025, it was in position 6/96, thus managing to position itself as a Q1 (Primer Cuartil), in the category Dermatology. Notably, the journal is positioned above the 90th percentile.

Independientemente del impacto esperado determinado por el canal de difusión, es importante destacar el impacto real observado de la propia aportación.

Según las diferentes agencias de indexación, el número de citas acumuladas por esta publicación hasta la fecha 2026-04-04:

  • WoS: 2
  • Scopus: 2
[+]

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2026-04-04:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 12.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 12 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 2.
  • The number of mentions on the social network X (formerly Twitter): 3 (Altmetric).
[+]